HOME >> BIOLOGY >> NEWS
Promising preclinical results with live attenuated H5N1 vaccines

Several approaches are in progress to develop vaccines against the avian flu variety of the influenza virus. Kanta Subbarao (National Institutes of Health) and colleagues are working on live attenuated vaccines, which have the potential to elicit a strong, broad, and lasting immune response. As they now report in the international open-access medical journal PLoS Medicine, results from mice and ferrets (the rodent flu model of choice) are very encouraging and pave the way to testing these vaccines in human volunteers.

The researchers developed vaccines using 3 artificially constructed, weakened forms of the influenza virus. The 3 vaccine viruses were constructed using flu virus proteins other than H and N from artificially weakened (attenuated) strains of influenza. These were combined with H and N proteins from H5N1 viruses isolated from human cases during three different years: 2004, 2003, and 1997. They grew larger quantities of the resulting viruses in hen eggs, and tested the vaccines in chickens, ferrets, and mice.

In tests of safety, the study found that, unlike the natural viruses from which they were derived, the vaccine strains did not cause death when injected into the bloodstream of chickens, and did not even cause persistent infection when given through the birds' breathing passages. Similarly, while the natural viruses were lethal in mice at various doses, the vaccine strains did not cause death even at the highest dose. In ferrets, infection with the vaccine strains was limited to the upper respiratory tract, while the natural viruses spread eadily to the lungs.

In tests of protection, all mice that had received any of the 3 vaccines survived following injection with any of the natural viruses (so-called viral challenge), while unvaccinated mice died following viral challenge. This occurred even though standard blood tests could not detect a strong immune responses following a single dose of vaccine. Challenge virus was
'"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
11-Sep-2006


Page: 1 2

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising new research on hereditary diseases
5. Promising cell protein may play role in infection and dry eye
6. Promising anti-TB compound finally can be synthesized with ease
7. Promising results in the battle against incurable ALS muscle disease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
10. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
11. Tramiprosate (Alzhemed) preclinical results published in Neurobiology of Aging

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... 2020 , ... Nine middle school teachers from eight states ... unique professional development program that provides advanced STEM (science, technology, engineering and math) ... , Created in partnership between the National Stem Cell Foundation and The Gatton ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to ... a near term focus on Type 2 diabetes and associated comorbidities. , Justin ... therapeutic areas and classes. As Chief Commercial Officer, Justin will lead Better ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 ... study, but what is the most effective way to complete one? Will the ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... “We are ... Third Wave Bioactives. “It’s the only technology of its kind on the market and ... of onions with the protective capacity of traditional cultured ingredients, creating a natural way ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., ... and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson ...
Breaking Biology Technology:
Cached News: